From the CBC:
“Health
Canada approves 4th COVID-19 vaccine as Pfizer agrees to accelerate deliveries”
Canada's
national campaign to inoculate people against the novel coronavirus got good
news on two fronts today: one vaccine maker now plans to accelerate its
deliveries and federal regulators have cleared a fourth COVID-19 vaccine for
use in this country. Prime Minister Justin Trudeau said today that, after
negotiations with the federal government, vaccine manufacturer Pfizer has
agreed to move up delivery of 3.5 million doses of its COVID-19 vaccine —
originally scheduled to arrive in the summer — to the next three months. The
company will deliver an additional 1.5 million doses in March, one million more
doses in April and another million in May, Trudeau said, bringing the total
number of doses of all approved vaccines expected to arrive by the end of this
month to 8 million.
The
announcement came just hours after Health Canada approved the use of Johnson
& Johnson's COVID-19 vaccine in Canada, providing provinces and territories
with another vaccine in addition to those previously approved from
Pfizer-BioNTech, Moderna and AstraZeneca-Oxford. A second version of the
AstraZeneca-Oxford vaccine that is biologically identical but manufactured
under different conditions by the Serum Institute of India under the brand name
"Covishield" has also been authorized. The Johnson & Johnson
vaccine, produced by the U.S. health care giant's pharmaceutical subsidiary,
Janssen Inc., is widely seen as one of the easiest to distribute because it
requires only one dose and can be stored for long periods of time at regular
refrigerator temperatures of 2 C to 8 C. "As long as it takes, we'll be
there with what people need to get through this pandemic. That means we're
sending more and more vaccines to the provinces and territories in the coming
weeks and months," Trudeau told a press conference today. The new Pfizer
delivery schedule and the Johnson & Johnson approval are expected to
accelerate Canada's vaccine rollout, which has so far lagged behind dozens of
other countries that have vaccinated more people per capita. In approving the Johnson & Johnson
vaccine, Health Canada's chief medical adviser said a review of data from a
clinical trial involving more than 44,000 participants found the shot is safe
and effective. "As with all COVID-19 vaccines, Health Canada authorized
the Janssen one after an independent and thorough scientific review for safety,
efficacy and quality," said Dr. Supriya Sharma. "After assessing all
the data, we concluded there was strong evidence that showed the benefits of
this vaccine outweigh the potential risks."
Health Canada
concluded the vaccine has an efficacy rate of 66.9 per cent in preventing
moderate to severe COVID-19 illness, and has authorized it for use for adults
aged 18 and older. While the vaccine is less effective than previously approved
vaccines from Pfizer-BioNTech and Moderna — both of which had efficacy rates of
90 per cent and above — Sharma said the shot offers strong protection against
the threats that matter most: serious illness, hospitalizations and death. "The
efficacy rate does not mean that following vaccination with a vaccine with 66 per
cent efficacy, that you will have a 34 per cent chance of contracting
COVID-19," said Sharma. "While each of the vaccines Health Canada has
authorized has different efficacy numbers, the reality is that you will have a
greatly reduced chance of getting COVID-19 with any of the ... vaccines that
have been authorized." Sharma said the shot remained effective against the
coronavirus variants first identified in South Africa and Brazil, as well as
the dominant strains circulating in the U.S. and Canada. Clinical trials are
also underway for other vaccines to see how safe they are for children between
the ages of 12 and 17, but Sharma suggested it will be months yet before
they're able to get the shots.
Delivery
schedule firming up Canada has ordered 10 million doses from Johnson &
Johnson, with options for up to 28 million more. While there is no timeline for
their delivery just yet, Trudeau said the president of Janssen Canada, Jorge
Bartolome, assured him this morning that the company is working to set up its
global supply chains and plans to meet its delivery commitments. Health Canada
has provided authorizations for manufacturing at two facilities — one in the
U.S. and one in Europe — but it's unclear right now from where Canada's doses will
be shipped. Procurement Minister Anita Anand said that the Johnson &
Johnson doses aren't expected to begin arriving until April, although the full
order of 10 million should be delivered by September. Canada now expects
to receive 36.5 million doses of the Pfizer-BioNTech, Moderna,
AstraZeneca-Oxford and the Covishield vaccines by the end of June. By the end
of September, Canada will have received 117.9 million doses. The June
number will grow once delivery schedules for the 20 million doses on order from
AstraZeneca and the 10 million from Johnson and Johnson are confirmed, Anand
said. "Because of our diversified procurement, we are able to see
an acceleration in doses coming to Canada from multiple suppliers," said
Anand. Pfizer's accelerated delivery schedule comes after major delays
in January and February, when the company upgraded its production lines at a
major factory in Belgium. Production problems also slowed the initial rollout
of the Johnson & Johnson vaccine in the U.S. after that country approved it
in February. The country was supposed to receive 10 million doses as soon as
the vaccine was approved, but only four million doses were shipped out March 1.
The U.S. expects to get another 16 million doses by the end of March and 100
million total by the end of June. Only one vaccine is still under review by
Health Canada — the Novavax product. Sharma said a decision on whether it can
be used in Canada is weeks or months away.
^ Canada is
slowly catching-up with the rest of the industrialized world. ^
https://www.cbc.ca/news/politics/johnson-johnson-covid19-vaccine-approved-1.5937900
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.